Form 4: MAIA Biotechnology Executive Gryaznov Acquires 200,000 Stock Options

Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., reports the acquisition of 200,000 stock options on February 10, 2025.

Summary

• Sergei Gryaznov, the Chief Scientific Officer of MAIA Biotechnology, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 10, 2025.
• Gryaznov acquired 200,000 stock options with an exercise price of $1.81.
• These options vest over a 4-year period, with 25% vesting on the first anniversary and the remainder vesting monthly over the following 36 months.
• The options expire on February 10, 2035.
• Gryaznov directly owns these derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. It's a routine filing, so the impact is moderate.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with the long-term success of the company. This is a standard method of compensation and retention.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Vesting schedules, such as the 4-year vesting with a 1-year cliff, are also standard practice.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates